ID

29224

Description

Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00660374

Lien

https://clinicaltrials.gov/show/NCT00660374

Mots-clés

Versions (1)
  1. 09/03/2018 09/03/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

9 mars 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes NCT00660374

Anglais

Eligibility Diabetes NCT00660374

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00660374
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes for at least 12 months
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
current nph treatment for at least 3 months - alone or as the only insulin in combination with oads
Description

NPH insulin | Antidiabetics Oral | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0021658
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3]
C0009429
body mass index (bmi) less than or equal to 40 kg/m2
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
hba1c less than or equal to 9.5%
Description

Glucohemoglobin measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0202054
fpg less than or equal to 12 mmol/l
Description

Plasma fasting glucose measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0583513
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with glucagon-like peptide 1 mimetics or dipeptityl peptidase iv inhibitors
Description

GLP-1 Mimetics | Dipeptidyl Peptidase 4 Inhibitors

Type de données

boolean

Alias
UMLS CUI [1]
C3273809
UMLS CUI [2]
C2917254
treatment with more than 1 iu/kg nph insulin daily
Description

NPH insulin IU/kg Daily

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021658
UMLS CUI [1,2]
C0439463
UMLS CUI [1,3]
C0332173
known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the investigator
Description

Loss of hypoglycemic warning | Recurrent severe hypoglycemia

Type de données

boolean

Alias
UMLS CUI [1]
C0342317
UMLS CUI [2]
C0342316
known or suspected allergy to trial products or related products
Description

Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0013230
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0013227
UMLS CUI [3,3]
C0439849
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0013227
UMLS CUI [4,4]
C0439849
receipt of any investigational drug within one month prior to this trial
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
any other condition that the investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers
Description

Condition Interferes with Study Subject Participation Status | Condition Interferes with Evaluation Research results | Shift worker

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2348568
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C1261322
UMLS CUI [2,4]
C0683954
UMLS CUI [3]
C0425104
Retour au début de la page

Similar models

Eligibility Diabetes NCT00660374

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00660374
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
type 2 diabetes for at least 12 months
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
NPH insulin | Antidiabetics Oral | Combined Modality Therapy
Item
current nph treatment for at least 3 months - alone or as the only insulin in combination with oads
boolean
C0021658 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3])
Body mass index
Item
body mass index (bmi) less than or equal to 40 kg/m2
boolean
C1305855 (UMLS CUI [1])
Glucohemoglobin measurement
Item
hba1c less than or equal to 9.5%
boolean
C0202054 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fpg less than or equal to 12 mmol/l
boolean
C0583513 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
GLP-1 Mimetics | Dipeptidyl Peptidase 4 Inhibitors
Item
treatment with glucagon-like peptide 1 mimetics or dipeptityl peptidase iv inhibitors
boolean
C3273809 (UMLS CUI [1])
C2917254 (UMLS CUI [2])
NPH insulin IU/kg Daily
Item
treatment with more than 1 iu/kg nph insulin daily
boolean
C0021658 (UMLS CUI [1,1])
C0439463 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
Loss of hypoglycemic warning | Recurrent severe hypoglycemia
Item
known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the investigator
boolean
C0342317 (UMLS CUI [1])
C0342316 (UMLS CUI [2])
Hypersensitivity Investigational New Drugs | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related
Item
known or suspected allergy to trial products or related products
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0013227 (UMLS CUI [4,3])
C0439849 (UMLS CUI [4,4])
Investigational New Drugs
Item
receipt of any investigational drug within one month prior to this trial
boolean
C0013230 (UMLS CUI [1])
Condition Interferes with Study Subject Participation Status | Condition Interferes with Evaluation Research results | Shift worker
Item
any other condition that the investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1261322 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])
C0425104 (UMLS CUI [3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial